Nexstim
8.2
EUR
-4.65 %
Corporate customer
NXTMH
First North Finland
Medical Equipment & Services
Health Care
5,297 following
-4.65%
+62.06%
+121.62%
+176.09%
+178.91%
+233.33%
+82.63%
+250.98%
-98.65%
Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.
Read moreMarket cap
58.73M EUR
Turnover
221.47K EUR
P/E (adj.) (24e)
-606.37
EV/EBIT (adj.) (24e)
18,722.76
P/B (24e)
15.57
EV/S (24e)
6.47
Dividend yield-% (24e)
-
Coverage
Financial calendar
27/2
2025
Annual report '24
Risk
Business risk
Valuation risk
Low
High
ShowingAll content types
Nexstim Receives NBS 6 Order from University Hospital in California
Distributor Orders Two Nexstim NBS 5 Systems
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Finnish University Hospital Orders Nexstim NBS System 5
Nexstim Receives an Upgrade Order from a German University Hospital
US Customer Orders Nexstim NBS System 5
Nexstim Plc’s New Shares Have Been Registered with the Finnish Trade Register
Nexstim Plc: Managers’ Transactions, Forss
Nexstim Plc: Managers’ Transactions, Niemistö

Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Nexstim Plc: Managers’ Transactions, Weckroth
Nexstim: Further evidence of cash flow turnaround
The Board of Directors of Nexstim Plc has decided on a directed share issue and issuance of special rights to Brainlab AG and on the conversion of a convertible bond
Inside Information: Nexstim Plc and Brainlab AG initiate collaboration by signing development and distributorship cooperation agreement and agreeing on a maximum of EUR 5,095,000 equity investment into Nexstim
New German Customer Orders Nexstim NBS System 5
Nexstim Receives System Order from University Hospital in United States
New Finnish Customer Orders Two Nexstim NBS 6 Systems
